慢性阻塞性肺疾病生物标记物的研究进展  

Latest research progress of biomarkers in chronic obstructive pulmonary disease

作　　者：邱海兵[1] 冯起校[2] 

机构地区：[1]广东医学院研究生院 [2]南方医科大学中西医结合医院呼吸内科,广东广州510000

出　　处：《中国现代医生》2016年第9期159-162,共4页China Modern Doctor

摘　　要：慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种常见病和多发病,给患者和社会带来巨大的经济负担。肺功能试验是诊断慢阻肺的金标准,慢阻肺急性加重的诊断则主要根据临床表现,缺乏量化指标。血清生物标记物是一种定量指标,有助于慢阻肺急性加重的诊断,可指导治疗和预测预后。本文对最新发现的血清生物标记物作一综述。Chronic obstructive pulmonary disease（COPD） is a common and frequently-occurring disease, which may lay a huge financial burden on the patients and the society. Respiratory function tests is the gold standard for the diagnosis of COPD, but the diagnosis of acute exacerbation of COPD is mainly based on clinical manifestations, thereby lacking quantitative indicators. Serum biomarkers is a quantitative indicator that is effective in the diagnosis, treatment,and prognosis of acute exacerbation of COPD. The most recently discovered serum biomarker is reviewed in this paper.

关 键 词：慢性阻塞性肺疾病 肺功能试验 急性加重 标记物 

分 类 号：R563.5[医药卫生—呼吸系统]